Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 7,248 matching trials from the live ClinicalTrials.gov search.

Filters: Detroit, Michigan Clear all

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 24
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 17 more

Conditions: EGFR Positive Solid Tumors
Interventions: IMGN289; Drug
Lead sponsor: ImmunoGen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Aortic Valve Disease, Aortic Valve Stenosis
Interventions: Foldax Tria Aortic Valve; Device
Lead sponsor: Foldax, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Indianapolis, Indiana • Wichita, Kansas • Detroit, Michigan + 2 more

Conditions: Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
Interventions: Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid; Drug · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Bay City, Michigan • Detroit, Michigan

Conditions: Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Recurrent, Platinum Resistant Ovarian Cancer, Endometrial Cancers
Interventions: OPB-201; Biological
Lead sponsor: Outpace Bio, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Detroit, Michigan + 2 more

Conditions: Leukaemia, Lymphocytic, Chronic
Interventions: Ofatumumab, Observation; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 43
States / cities: Gilbert, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 37 more

Conditions: Major Depressive Disorder
Interventions: CP-601,927, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 58
States / cities: Little Rock, Arkansas • Beverly Hills, California • Garden Grove, California + 44 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: Autistic Disorder
Interventions: Fluoxetine (prozac); Drug
Lead sponsor: Neuropharm; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Phoenix, Arizona • Sacramento, California • Smyrna, Georgia + 10 more

Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Interventions: Non-interventional Study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 488
States / cities: Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 378 more

Conditions: Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 44
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more

Conditions: Pemphigus Vulgaris
Interventions: Dapsone; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 8
States / cities: Chicago, Illinois • Detroit, Michigan • Camden, New Jersey + 4 more

Conditions: Lymphoma, Low-Grade
Interventions: FavId (Id-KLH) active immunotherapy; Biological
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Hepatitis D
Interventions: EBP921; Drug
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: San Francisco, California • Detroit, Michigan

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: XT-150; Biological
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 4
States / cities: Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Generalized Myasthenia Gravis
Interventions: M281, Placebo; Drug · Other
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Cystic Fibrosis
Interventions: tiotropium Respimat® inhaler, Placebo Respimat® inhaler; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 15
States / cities: Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging; Radiation · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 678
States / cities: Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more

Conditions: Refractory Status Epilepticus
Interventions: Perampanel; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 791
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more

Conditions: Infant, Newborn, Hypotension, Blood Pressure
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Search by objective public record fields.

A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Extended Management and Measurement of Autism

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Safety Study of XT-150 in Participants With ALS

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Tiotropium Bromide in Cystic Fibrosis

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Open Label Extension Study of PREOS

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Hypotension in Neonates